Latest News for: btk
Edit
Independent Record
07 Oct 2026
REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26
Live case showcases successful below-the-knee revascularization with two MOTIV® scaffolds; late-breaking analysis shows higher efficacy endpoint rates with MOTIV versus balloon angioplasty in both Rutherford 4 and Rutherford 5 CLTI populations ... .
Edit
Morgan Citizen
05 Oct 2026
InventHelp Inventor Develops Spearfishing Target Game for Swimming Pools (BTK-900)
PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- "I wanted to create a new target game for swimming pools and ponds that would simulate spear fishing," said an inventor, from Vincent, Ala., "so I invented the AQUA HUNTER. My design would be ... .
Edit
Watauga Democrat
03 Oct 2026
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA ...
INDIANAPOLIS, Oct.
Edit
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
PR Newswire 02 Oct 2026
Edit
The Milton Standard Journal
30 Sep 2026
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both ...
Edit
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing ...
Nasdaq Globe Newswire 30 Sep 2026
RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company’s New Drug ...
Edit
Medtronic earns FDA Breakthrough Device designation for IN.PACT™ BTK drug-coated balloon (Medtronic plc)
Public Technologies 30 Sep 2026
Edit
Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis (Roche Holding AG)
Public Technologies 30 Sep 2026
Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton's tyrosine kinase (BTK) inhibitor with an optimised pharmacokinetics (PK) profile.
Edit
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis (Genentech Inc)
Public Technologies 30 Sep 2026
Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton's tyrosine kinase (BTK) inhibitor with an optimized pharmacokinetics (PK) profile.
Edit
InventHelp Inventor Develops Home Mail Delivery System (BTK-432)
PR Newswire 13 Jul 2026
PITTSBURGH, July 13, 2026 /PRNewswire/ -- "I am disabled and walk with a cane ... As a result, it saves time and effort ... 25-BTK-432, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext ... .
Edit
An InventHelp 123Invent Client Develops Hunting Product for Attracting Game (BTK-458)
PR Newswire 09 Jul 2026
PITTSBURGH, July 9, 2026 /PRNewswire/ -- "I thought there could be a better way to dangle scented wafers for attracting deer and other game animals when hunting," said an inventor from Ranburne, Alabama ... InventHelp Invention Spotlight ... and Canada ... 21% ... .
- 1
- 2
- Next page »